The eBooks we sell are sold as a single-user licence and are intended for the end user only.
The sale of some eBooks are restricted to certain countries. To alert you to such restrictions, please select the country of the billing address of your credit or debit card you wish to use for payment.
For further information see https://www.wildy.com/ebook-formats
Once the order is confirmed an e-mail will be sent to you to allow you to download the eBook. For UK purchases this will be automatic. For purchases outside the UK a member of staff will need to confirm the sale. (Staff are available to do this during normal business hours, Mon-Fri 8:30-17:00 UK time)
All eBooks are supplied firm sale and cannot be returned. If you believe there is a fault with your eBook then contact us on ebooks@wildy.com and we will help in resolving the issue. This does not affect your statutory rights.
Due to a technical issue some ebooks are not available to order.
Pharmaceutical Test Data Exclusivity is designed to provide expert guidance, chapter by chapter, on test data exclusivity rights for innovative pharmaceutical products in twenty-two major markets worldwide. Data exclusivity gives pharmaceutical companies a limited period of time in which clinical test data are exclusive to the innovator. Internationally, however, aside from prohibition against unfair commercial use, there are no specifics as to how these data are protected. This book will be the starting point for innovator pharmaceutical companies and their advisers to evaluate data exclusivity rules and opportunities around the world.
This book originated from a project conducted by the Pharma Committee of the International Association for the Protection of Intellectual Property (AIPPI). In addition to explaining the available regulatory data protection in each jurisdiction, contributors of chapters in this book, who are local experts, committee members and observers, provide detailed information and guidance on the degree to which test data exclusivity may be achieved in such areas of pharmaceutical research as the following:
As an unmatched starting point for innovator pharmaceutical companies and their advisers to evaluate data exclusivity rules and opportunities around the world, this book will be an invaluable resource for IP professionals, governments, non-governmental organizations, and international organizations to promote and share IP laws and practices. By providing detailed information on the cutting-edge issues of IP and proposing an adequate balanced position to frame the issues, this book will be a valuable resource for pharmaceutical innovators on the various data exclusivity provisions available for innovative drug products in the listed countries.
